Uckert S, Stief C G, Odenthal K P, Truss M C, Lietz B, Jonas U
Hannover Medical School, Department of Urology, Germany.
Arzneimittelforschung. 2000 May;50(5):456-60. doi: 10.1055/s-0031-1300230.
The spasmolytic activity of flavoxate (CAS 15301-69-6) and the anticholinergic agents oxybutynin (CAS 5633-20-5), tolterodine (CAS 124937-51-5) and trospium chloride (CAS 10405-02-4), all of which are commonly utilized in the treatment of urinary incontinence, on muscarinic tension and electrically evoked contractions of isolated human detrusor smooth muscle strips was studied using the organ bath technique. Within the concentration ranges tested (trospium chloride 10(-11)-10(-6) mol/l, flavoxate and oxybutynin 10(-9)-10(-5) mol/l, tolterodine 10(-10)-10(-5) mol/l), each drug caused a concentration-dependent relaxation of the tension elicited by muscarinic stimulation and dose-dependently attenuated the contractions induced by electrical field stimulation (EFS). The effects of trospium chloride and tolterodine on carbachol-induced muscarinic tension were more pronounced than those of oxybutynin, while trospium chloride and oxybutynin were most effective in inhibiting the contractions induced by EFS. Flavoxate was significantly less effective than all other drugs tested. Regardless the individual drug concentrations needed for maximal efficacy, the potency of oxybutynin and flavoxate to reverse muscarinic tension and attenuate EFS-evoked contractions was almost comparable while tolterodine and trospium chloride were more effective in relaxing the muscarinic tension of the detrusor strip preparations than causing inhibition of EFS-induced contractions. Our results again underline the ratio for the use of nortropane analogues (trospium chloride) and phenylpropylamine cresols (tolterodine) in the treatment of frequency, urgency and urge incontinence secondary to an overactive bladder.
黄酮哌酯(CAS 15301-69-6)以及抗胆碱能药物奥昔布宁(CAS 5633-20-5)、托特罗定(CAS 124937-51-5)和氯化曲司氯铵(CAS 10405-02-4)都常用于治疗尿失禁,采用器官浴技术研究了它们对毒蕈碱张力以及离体人逼尿肌平滑肌条电诱发收缩的解痉活性。在所测试的浓度范围内(氯化曲司氯铵10⁻¹¹ - 10⁻⁶ mol/L,黄酮哌酯和奥昔布宁10⁻⁹ - 10⁻⁵ mol/L,托特罗定10⁻¹⁰ - 10⁻⁵ mol/L),每种药物均引起毒蕈碱刺激所诱发张力的浓度依赖性松弛,并剂量依赖性地减弱电场刺激(EFS)所诱发的收缩。氯化曲司氯铵和托特罗定对卡巴胆碱诱发的毒蕈碱张力的作用比奥昔布宁更明显,而氯化曲司氯铵和奥昔布宁在抑制EFS诱发的收缩方面最有效。黄酮哌酯的效果明显低于所有其他测试药物。无论达到最大疗效所需的个体药物浓度如何,奥昔布宁和黄酮哌酯逆转毒蕈碱张力以及减弱EFS诱发收缩的效力几乎相当,而托特罗定和氯化曲司氯铵在松弛逼尿肌条制剂的毒蕈碱张力方面比抑制EFS诱发的收缩更有效。我们的结果再次强调了使用去甲托烷类似物(氯化曲司氯铵)和苯丙胺甲酚(托特罗定)治疗膀胱过度活动症继发的尿频、尿急和急迫性尿失禁的合理性。